Save time and jump to the most important pieces.
NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") is pleased to provide an update on its previously-announced pending strategic acquisition of an equity stake in PsyLabs, and progress with PsyLabs' collaboration with its contract drug manufacturing organization (CDMO). This collaboration is key to advancing the development of PsyLabs' nature-derived psychedelic active pharmaceutical ingredients (APIs) towards E.U. Good Manufacturing Practices (GMP) certification. In September 2024, Psyence Biomed entered into a worldwide, exclusive royalty-bearing IP licensing agreement with PsyLabs for pharmaceutical-grade, EU GMP certifi
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its previously announced proposed acquisition of Clairvoyant Therapeutics, Inc. Following the completion of necessary due diligence and other pre-closing activities specified in the conditional binding term sheet that was announced on September 9, 2024, Psyence Biomed has decided not to proceed with the acquisition at this time. Psyence Biomed continues to advance its recently initiated Phase IIb clinical trial of nature derived psilocybin in conjunction with psychotherapy as a potential treatment fo
NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has entered into a conditional share sale agreement with Psyence Group (CSE:PSYG) (as seller) for the acquisition of an 11.13% stake in privately-held PsyLabs, a company focused on the production of psychedelic active pharmaceutical ingredients (APIs) and extracts for use in research, clinical trials and drug development ("Proposed Acquisition"). Per the terms of the Proposed Acquisition, Psyence Biomed will issue to Psyence Group shares of its common stock valued at $1.1 million dollars, at a price of $0.55 per share, in exchange for Psyence Group's
U.S. stocks traded mixed this morning, with the Dow Jones gaining over 200 points on Thursday. Following the market opening Thursday, the Dow traded up 0.53% to 40,064.06 while the NASDAQ fell 1.25% to 17,124.88. The S&P 500 also fell, dropping, 0.38% to 5,406.26. Check This Out: Jim Cramer: This Tech Stock Is ‘Absolutely Terrific,’ But Jumia? It’s Not Making A Lot Of Money Leading and Lagging SectorsReal estate shares jumped by 1.4% on Wednesday. In trading on Wednesday, information technology shares fell by 2.5%. Top Headline Honeywell International Inc. (NASDAQ:HON) reported second-quarter results and lowered FY24 EPS guidance. Adjusted EPS was $2.49 (+8% Y/Y), beat
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings
EFFECT - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)
424B3 - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)
6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)